PTC Therapeutics Reports Record Q3 2026 Revenue and Raises Full-Year Guidance
PTC Therapeutics (PTCT) reported strong third-quarter 2026 results, highlighted by total revenue of $358 million, a significant increase from $211 million in the same period last year. This growth was primarily driven by product revenue, which surged over 100% year-over-year to $276 million, fueled by the successful global launch and adoption of Sephience. Following these results, management raised its full-year total revenue guidance to a range of $1.29 billion to $1.32 billion. While the company faces pricing headwinds from generic competition in its DMD franchise, strong royalty income from Evrysdi and steady patient enrollment for Sephience have bolstered the balance sheet, which holds $2.13 billion in cash and marketable securities. The company remains on track to achieve cash flow breakeven by the end of 2026.
Topics: Acquisition Drug Revenue Financial Guidance Product Sales Revenue Growth